# MAY 262005

# 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS Direct HDL Cholesterol Method for ADVIA@ Modular System (IMs) TM

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of the Safe Medical Device Act of 1990 and 21 CFR 807.92.

The assigned 510(k) number is: Ko 50 6 3 2

# 1. Intended Use

This in vitro method is intended to quantitatively measure HDL Cholesterol in human serum and plasma on the Bayer ADVIA $\mathfrak { P }$ IMS systems. Measurements of HDL Cholesterol are used in assessing cardiovascular risk.

2. Predicate Device

<table><tr><td rowspan=1 colspan=1>Product Name</td><td rowspan=1 colspan=1>Reagent Part #</td><td rowspan=1 colspan=1>Calibrator Part #</td></tr><tr><td rowspan=1 colspan=1>Bayer ADVIA 1650Direct HDL Cholesterol</td><td rowspan=1 colspan=1>08058065</td><td rowspan=1 colspan=1>00309530(B03-4763-01)</td></tr></table>

3. Device / Method

<table><tr><td rowspan=1 colspan=1>Product Name</td><td rowspan=1 colspan=1>Reagent Part #</td><td rowspan=1 colspan=1>Calibrator Part #</td></tr><tr><td rowspan=1 colspan=1>ADVIA IMSDirect HDL Cholesterol</td><td rowspan=1 colspan=1>07986694</td><td rowspan=1 colspan=1>00309530(B03-4763-01)</td></tr></table>

# 4. Performance

A. Imprecision   

<table><tr><td rowspan=1 colspan=2>ADVIA IMS</td></tr><tr><td rowspan=1 colspan=1>Levelmg/dL</td><td rowspan=1 colspan=1>TotalCV (%)</td></tr><tr><td rowspan=1 colspan=1>37.04</td><td rowspan=1 colspan=1>3.3</td></tr><tr><td rowspan=1 colspan=1>54.84</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>82.55</td><td rowspan=1 colspan=1>1.8</td></tr></table>

<table><tr><td rowspan=1 colspan=2>ADVIA 1650</td></tr><tr><td rowspan=1 colspan=1>Levelmg/dL</td><td rowspan=1 colspan=1>TotalCV(%)</td></tr><tr><td rowspan=1 colspan=1>36.15</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>55.00</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>76.92</td><td rowspan=1 colspan=1>1.9</td></tr></table>

C. Correlation ( $\mathbf { Y } =$ ADVIA IMS, $\mathbf { X } = \mathbf { C } \mathbf { 0 }$ mparison system)   

<table><tr><td rowspan=1 colspan=1>Specimen type</td><td rowspan=1 colspan=1>ComparisonSystem (X)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>Syxmg/dL</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>IMS SampleRangemg/dL</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>ADVIA 1650</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>Y=0.986X + 1.16</td><td rowspan=1 colspan=1>2.29</td><td rowspan=1 colspan=1>0.988</td><td rowspan=1 colspan=1>15 to 88</td></tr></table>

# D. Interfering Substances

<table><tr><td rowspan=1 colspan=1>InterferingSubstance</td><td rowspan=1 colspan=1>Interfering Sub.Conc. (mg/dL)</td><td rowspan=1 colspan=1>HDL CholesterolConcentration(mg/dL)</td><td rowspan=1 colspan=1>Effect(% change)</td></tr><tr><td rowspan=1 colspan=1>Bilinubin(unconjugated)</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>44.3</td><td rowspan=1 colspan=1>-1.1%</td></tr><tr><td rowspan=1 colspan=1>Bilirubin(conjugated)</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>46.5</td><td rowspan=1 colspan=1>-7.3%</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>46.2</td><td rowspan=1 colspan=1>-9.5%</td></tr><tr><td rowspan=1 colspan=1>Lipids (Intralipid)</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>45.0</td><td rowspan=1 colspan=1>-4.9%</td></tr></table>

# E. Analytical Range

7 to ${ 9 0 } \mathrm { m g / d L }$ .

![](images/55b457abc4f1cc9307e2a153f0f9d6bfab6c9e6986b12d5e89894e908c624513.jpg)

Date

Andres Holle   
Regulatory Affairs   
Bayer Corporation   
511 Benedict Avenue   
Tarrytown, New York, 10591 - 5097

# MAY 262005

Mr. Andres Holle   
Manager, Regulatory Affairs   
Bayer HealthCare   
Diagnostics Division   
511 Benedict Avenue   
Tarrytown, NY 10591

Re: k050632 Trade/Device Name: Direct HDL Cholesterol for the ADVIA IMS Regulation Number: 21 CFR 862.1475 Regulation Name: Lipoprotein test system Regulatory Class: Class I Product Code: LBS Dated: March 4, 2005 Received: March 9, 2005

Dear Mr. Holle:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, isting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class I (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); Iabeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2â€“

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Caoll. Bemam

Carol C. Benson, M.A.   
Acting Director   
Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and   
Radiological Health

# Indications for Use

510(k) Number: K 05 063 2

Device Name: Direct HDL Cholesterol for the ADVIA IMS

Indications for Use:

The Bayer ADVIA IMS Direct HDL Cholesterol (D-HDL) method is for in vitro diagnostic use to measure HDL Cholesterol in human serum and plasma. Such measurements are used in the risk assessment of cardiovascular diseases.

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Division Sign-Off

# Office of In Vitro Diagnostic Device Evaluation and Safety

510(k)k050632